BR112022019202A2 - Oligopeptídeo, composição farmacêutica, composição, e, método para reduzir a inflamação intestinal em um ser humano, para promover crescimento em um animal e para realçar conversão de alimento em um animal - Google Patents

Oligopeptídeo, composição farmacêutica, composição, e, método para reduzir a inflamação intestinal em um ser humano, para promover crescimento em um animal e para realçar conversão de alimento em um animal

Info

Publication number
BR112022019202A2
BR112022019202A2 BR112022019202A BR112022019202A BR112022019202A2 BR 112022019202 A2 BR112022019202 A2 BR 112022019202A2 BR 112022019202 A BR112022019202 A BR 112022019202A BR 112022019202 A BR112022019202 A BR 112022019202A BR 112022019202 A2 BR112022019202 A2 BR 112022019202A2
Authority
BR
Brazil
Prior art keywords
animal
composition
oligopeptide
promoting growth
human
Prior art date
Application number
BR112022019202A
Other languages
English (en)
Portuguese (pt)
Inventor
Disston Nalle Horace Jr
Kaltenboeck Bernhard
Original Assignee
Nutrivert Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutrivert Llc filed Critical Nutrivert Llc
Publication of BR112022019202A2 publication Critical patent/BR112022019202A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23K20/10Organic substances
    • A23K20/142Amino acids; Derivatives thereof
    • A23K20/147Polymeric derivatives, e.g. peptides or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/5555Muramyl dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Fodder In General (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
BR112022019202A 2020-03-26 2021-03-25 Oligopeptídeo, composição farmacêutica, composição, e, método para reduzir a inflamação intestinal em um ser humano, para promover crescimento em um animal e para realçar conversão de alimento em um animal BR112022019202A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063000364P 2020-03-26 2020-03-26
PCT/US2021/024142 WO2021195372A1 (en) 2020-03-26 2021-03-25 Lipophilic enantiomers of desacetylglucosamine muramyl dipeptide with anti-inflammatory and growth promoting activity

Publications (1)

Publication Number Publication Date
BR112022019202A2 true BR112022019202A2 (pt) 2022-11-08

Family

ID=77892334

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022019202A BR112022019202A2 (pt) 2020-03-26 2021-03-25 Oligopeptídeo, composição farmacêutica, composição, e, método para reduzir a inflamação intestinal em um ser humano, para promover crescimento em um animal e para realçar conversão de alimento em um animal

Country Status (13)

Country Link
US (1) US12492222B2 (https=)
EP (1) EP4126040B1 (https=)
JP (1) JP7667177B2 (https=)
KR (1) KR102897673B1 (https=)
CN (1) CN115605226A (https=)
AU (1) AU2021241625B2 (https=)
BR (1) BR112022019202A2 (https=)
CA (1) CA3172936A1 (https=)
ES (1) ES3014076T3 (https=)
MX (1) MX2022011751A (https=)
PL (1) PL4126040T3 (https=)
WO (1) WO2021195372A1 (https=)
ZA (1) ZA202210586B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160319278A1 (en) 2015-04-03 2016-11-03 University Of Massachusetts Fully stabilized asymmetric sirna
WO2017030973A1 (en) 2015-08-14 2017-02-23 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
US10478503B2 (en) 2016-01-31 2019-11-19 University Of Massachusetts Branched oligonucleotides
JP7406793B2 (ja) 2017-06-23 2023-12-28 ユニバーシティー オブ マサチューセッツ 2テイル自己デリバリー型siRNAおよび関連方法
US11279930B2 (en) 2018-08-23 2022-03-22 University Of Massachusetts O-methyl rich fully stabilized oligonucleotides
CN113614232A (zh) 2019-01-18 2021-11-05 马萨诸塞大学 动态药代动力学修饰锚
US11820985B2 (en) 2019-03-26 2023-11-21 University Of Massachusetts Modified oligonucleotides with increased stability
KR20220047989A (ko) 2019-08-09 2022-04-19 유니버시티 오브 매사추세츠 Snp를 표적화하는 화학적으로 변형된 올리고뉴클레오타이드
US12365894B2 (en) 2019-09-16 2025-07-22 University Of Massachusetts Branched lipid conjugates of siRNA for specific tissue delivery
ES3014076T3 (en) 2020-03-26 2025-04-16 Nutrivert Inc Lipophilic enantiomers of desacetylglucosamine muramyl dipeptide with anti-inflammatory and growth promoting activity
JP7837560B2 (ja) 2020-03-26 2026-03-31 ユニバーシティー オブ マサチューセッツ 安定性の向上を有する修飾オリゴヌクレオチドの合成
WO2021242883A1 (en) 2020-05-26 2021-12-02 University Of Massachusetts Synthetic oligonucleotides having regions of block and cluster modifications
WO2024102639A1 (en) * 2022-11-08 2024-05-16 The Scripps Research Institute N-arylpyrazole nod2 agonists as promoters of immune checkpoint inhibitor therapy

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2428051A1 (fr) * 1978-06-05 1980-01-04 Anvar Nouveaux composes du type muramyl-peptide et medicaments les contenant
SI9011830B (sl) 1990-09-27 1999-12-31 Univerza V Ljubljani, Fakulteta Za Farmacijo Novi N-acildipeptidi, postopki za njihovo pripravo in farmacevtski pripravki, ki jih vsebujejo
JPH0655107B2 (ja) 1991-03-13 1994-07-27 全国農業協同組合連合会 家畜,家禽,および魚介類用の抗仮性狂犬病ならびに抗病性飼料および飼料用添加物
AU3361093A (en) 1992-01-20 1993-08-03 Peptech (Uk) Limited Use of muramyl peptides for enhancing animal production
MX9301789A (es) * 1992-04-03 1993-10-01 Iaf Biochem Int Nuevos oligopeptidos lipofilicos con actividad inmunomoduladora.
US5976580A (en) 1995-06-07 1999-11-02 Novus International, Inc. Nutrient formulation and process for enhancing the health, livability, cumulative weight gain or feed efficiency in poultry and other animals
CN1956707B (zh) 2004-03-26 2010-12-29 力奇制药公司 包含n-(2-(2-苯二酰亚氨基乙氧基)-乙酰基)-l-丙氨酰基-d-谷氨酸(lk-423)的耐胃酸的药物剂型
KR20090057035A (ko) 2006-08-21 2009-06-03 유나이티드 세러퓨틱스 코오포레이션 바이러스 감염의 치료를 위한 병용 요법
WO2008070564A1 (en) 2006-12-01 2008-06-12 The Government Of The U.S.A, As Represented By The Secretary, Departmentof Health And Human Services Uses of muramyl dipeptide (mdp) for treating inflammation
WO2009033690A1 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Bfgf (119-126) for therapeutic applications
CA2708044C (en) 2007-12-06 2017-01-03 Mary Irene Wray Combination therapies using melengestrol acetate and zilpaterol or its salts
CN101756026A (zh) 2008-12-11 2010-06-30 天津瑞贝特科技发展有限公司 增强虾、蟹硬壳速度的营养组合物及其制备方法、应用
DE102009002044A1 (de) 2009-03-31 2010-10-07 Evonik Degussa Gmbh Dipeptide als Futtermitteladditive
EP2711013A4 (en) 2011-05-18 2015-03-04 Ajinomoto Kk IMMUNSTIMULANDS FOR ANIMALS, FEED THEREFOR AND MANUFACTURING PROCESS THEREFOR
CN102578414B (zh) 2012-02-23 2014-01-01 青岛绿曼生物工程有限公司 促进猪生长育肥、提高免疫力的复方蜂胶饲料添加剂及其制备方法
US9884084B2 (en) 2012-05-16 2018-02-06 Snu R&Db Foundation Bone loss preventing and bone regeneration or bone formation promoting pharmaceutical composition comprising muramyl dipeptide
EP2975046A1 (en) * 2014-07-16 2016-01-20 The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth Novel compounds
WO2017068149A1 (en) 2015-10-21 2017-04-27 Cysal Gmbh Aspartyl-dipeptides for aquaculture
US10927147B2 (en) * 2015-12-10 2021-02-23 Bharat Biotech International Limited Muramyl peptide derivative compound, synthesis and uses thereof
CN109562158A (zh) 2016-06-23 2019-04-02 纽特莱特公司 在动物中促进生长和提高饲料转化率的方法
TWI634902B (zh) 2017-10-28 2018-09-11 醫療財團法人徐元智先生醫藥基金會亞東紀念醫院 Use of glucosamine peptide compounds for the treatment of abnormal liver metabolism
CN110191892B (zh) 2018-07-23 2022-04-26 深圳市健元医药科技有限公司 丙氨酸—赖氨酸—谷氨酸三肽衍生物及其应用
ES3014076T3 (en) 2020-03-26 2025-04-16 Nutrivert Inc Lipophilic enantiomers of desacetylglucosamine muramyl dipeptide with anti-inflammatory and growth promoting activity

Also Published As

Publication number Publication date
US12492222B2 (en) 2025-12-09
AU2021241625A1 (en) 2022-11-10
CN115605226A (zh) 2023-01-13
MX2022011751A (es) 2022-12-02
JP2023518973A (ja) 2023-05-09
EP4126040A1 (en) 2023-02-08
WO2021195372A1 (en) 2021-09-30
NZ792610A (en) 2025-07-25
PL4126040T3 (pl) 2025-04-28
EP4126040A4 (en) 2024-04-24
ES3014076T3 (en) 2025-04-16
AU2021241625B2 (en) 2025-04-24
CA3172936A1 (en) 2021-09-30
EP4126040B1 (en) 2025-02-19
US20230174577A1 (en) 2023-06-08
KR102897673B1 (ko) 2025-12-09
ZA202210586B (en) 2023-05-31
JP7667177B2 (ja) 2025-04-22
EP4126040C0 (en) 2025-02-19
KR20220158773A (ko) 2022-12-01

Similar Documents

Publication Publication Date Title
BR112022019202A2 (pt) Oligopeptídeo, composição farmacêutica, composição, e, método para reduzir a inflamação intestinal em um ser humano, para promover crescimento em um animal e para realçar conversão de alimento em um animal
BR112018072064B8 (pt) Uso de triglicerídeos de cadeia média para preparação de composições nutricionais para proteção cardíaca em animais de estimação
DE69114498D1 (de) Kurzbettige, einfach ungesättigte fettsäuren enthaltende nahrungsmittel und pharmazeutische zusammensetzungen sowie deren anwendungen.
AR003108A1 (es) Compuestos con propiedades de liberacion de la hormona del crecimiento, composicion farmaceutica que los contienen, el uso de los mismos para la preparación de un medicamento.
ES2162586B1 (es) Composicion que comprende aceites ozonizados y/o otros productos naturales y/o sinteticos ozonizados, y su empleo en composiciones farmaceuticas, cosmeticas, dieteticas o de suplementos alimentarios, en los campos humano y veterinario
CA2260265A1 (fr) Nouvelle utilisation de phospholipides d'origine animale en therapeutique et/ou dietetique
DK0973515T3 (da) Faste sammensætninger, der er egnet til oral indgivelse, hvilke sammensætninger omfatter et alkanoyl-L-carnitinmagnesiumcitrat
ATE220659T1 (de) Feste zusammensetzungen für orale verabreichung die l-carnitine oder alkanoyl-l-carnitin- magnesium-fumarat enthalten
Malone Managing chronic arthritis
CL2020002800A1 (es) Composiciones y mètodos para alimentar mamìferos
DE602006011127D1 (de) Fettsäure-benzenediol-derivate sowie herstellungs- und verwendungsverfahren dafür
ES2186694T3 (es) Vacuna bacteriana para el tratamiento de necrosis hepatica causada por f. necrophorum.
BRPI0419209A2 (pt) mÉtodo de aumentar a palatabilidade de um produto de raÇço extrusado para animais de estimaÇço, composiÇço intensificadora da palatabilidade para raÇço de animal de estimaÇço extrusada, e, composiÇço de raÇço extrusada para animal de estimaÇço
PT971880E (pt) Composicoes solidas adequadas para administracao oral compreendendo sais nao-hidroscopicos de l-carnitina e alcanoil-l-carnitina com acido 2-aminoetanossulfonico
BR9808908A (pt) Composições sólidas adequadas para administração oral que compreendem l-carnitina ou tartarato de alcanoil-l-carnitina colina
MX383324B (es) Suplemento alimenticio a base de ferulato de etilo
BR132020026288E2 (pt) Composição a base de extrato de pterodon pubescens benth., sua formulação e usos
AR117097A1 (es) Formulaciones farmacéuticas para una administración subcutánea
ES2087027B1 (es) Suplementos nutricionales termogeneticos, alimentos que los contienen y aplicaciones.
SV1999000067A (es) Proteina humana c polipeptida ref. x-12279
BRPI0415111A (pt) composição farmacêutica que compreende o ácido 5-metil-2-( 2`-cloro-6`-fluoroanilino) fenilacético
PA8567601A1 (es) Sal agonista del receptor b3-adrenergico, sus formulaciones y sus usos
RU2012127592A (ru) Кормовая добавка для забойного молодняка норок

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: NUTRIVERT INC. (US)